ES2177346T3 - Formulaciones de ranolazina de liberacion lenta. - Google Patents

Formulaciones de ranolazina de liberacion lenta.

Info

Publication number
ES2177346T3
ES2177346T3 ES99968627T ES99968627T ES2177346T3 ES 2177346 T3 ES2177346 T3 ES 2177346T3 ES 99968627 T ES99968627 T ES 99968627T ES 99968627 T ES99968627 T ES 99968627T ES 2177346 T3 ES2177346 T3 ES 2177346T3
Authority
ES
Spain
Prior art keywords
release
slow release
ranolazine
release ranolazine
ranolazine formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99968627T
Other languages
English (en)
Inventor
Andrew A Wolff
Fiona Baker
John Langridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Syntex USA LLC
Original Assignee
Syntex USA LLC
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2177346(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex USA LLC, CV Therapeutics Inc filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2177346T3 publication Critical patent/ES2177346T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Forma de dosificación farmacéutica de liberación lenta para utilización oral que comprende aproximadamente el 50% en peso de ranolazina y por lo menos un aglutinante dependiente del pH que inhibe la liberación de ranolazina cuando la forma galénica de liberación lenta se somete a un medio acuoso que tiene el pH del estómago y que favorece la liberación de una cantidad terapéutica de ranolazina en una solución acuosa que tiene un pH por encima de aproximadamente 4,5.
ES99968627T 1998-09-10 1999-09-09 Formulaciones de ranolazina de liberacion lenta. Expired - Lifetime ES2177346T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (1)

Publication Number Publication Date
ES2177346T3 true ES2177346T3 (es) 2002-12-01

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99968627T Expired - Lifetime ES2177346T3 (es) 1998-09-10 1999-09-09 Formulaciones de ranolazina de liberacion lenta.
ES99948196T Expired - Lifetime ES2234302T3 (es) 1998-09-10 1999-09-09 Formulaciones de ranolacina de liberacion sostenida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99948196T Expired - Lifetime ES2234302T3 (es) 1998-09-10 1999-09-09 Formulaciones de ranolacina de liberacion sostenida.

Country Status (33)

Country Link
US (14) US6303607B1 (es)
EP (3) EP1527779A1 (es)
JP (2) JP3745621B2 (es)
KR (1) KR100475759B1 (es)
CN (2) CN1193757C (es)
AR (3) AR022085A1 (es)
AT (2) ATE285774T1 (es)
AU (4) AU744071B2 (es)
BR (2) BR9913553A (es)
CA (2) CA2343376C (es)
CY (1) CY2008020I1 (es)
CZ (2) CZ301375B6 (es)
DE (3) DE122008000065I1 (es)
DK (2) DK1109558T3 (es)
ES (2) ES2177346T3 (es)
FR (1) FR09C0001I2 (es)
GE (1) GEP20053420B (es)
HK (2) HK1040060A1 (es)
HU (2) HUP0104088A3 (es)
IL (6) IL141893A0 (es)
LU (1) LU91504I2 (es)
MX (2) MXPA01002598A (es)
NL (1) NL300371I2 (es)
NO (4) NO320986B1 (es)
NZ (2) NZ510386A (es)
PL (3) PL202207B1 (es)
PT (2) PT1109558E (es)
RU (2) RU2207856C2 (es)
SI (2) SI1096937T1 (es)
TR (2) TR200101261T2 (es)
TW (1) TWI241911B (es)
UA (2) UA75027C2 (es)
WO (2) WO2000013687A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2004505886A (ja) 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
KR20050005437A (ko) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
EP2332540A1 (en) * 2002-05-21 2011-06-15 Cv Therapeutics, Inc. Administration of ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
CN101098682A (zh) * 2005-01-06 2008-01-02 Cv医药有限公司 包括雷诺嗪的缓释药物制剂
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
JP2009502957A (ja) * 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
EP1998387B1 (en) * 2006-03-17 2015-04-22 Konica Minolta Holdings, Inc. Organic electroluminescent device, display and illuminating device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080214555A1 (en) * 2007-02-13 2008-09-04 Markus Jerling Use of ranolazine for the treatment of cardiovascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
EP2155697B1 (en) * 2007-06-13 2012-11-28 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
EP2480234B1 (en) 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (es) 2011-07-01 2018-04-28
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TW201717919A (zh) * 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine

Also Published As

Publication number Publication date
DE122008000065I1 (de) 2009-04-09
KR100475759B1 (ko) 2005-03-10
NO20054324L (no) 2001-04-30
US20030100566A1 (en) 2003-05-29
NO20011191L (no) 2001-04-30
WO2000013686A3 (en) 2000-07-06
TR200101262T2 (tr) 2001-12-21
EP1096937B9 (en) 2007-02-28
CZ301341B6 (cs) 2010-01-20
US6617328B2 (en) 2003-09-09
CA2342390A1 (en) 2000-03-16
HK1044284A1 (en) 2002-10-18
BR9913626A (pt) 2001-12-04
US6620814B2 (en) 2003-09-16
HUP0103844A3 (en) 2002-11-28
EP1109558A2 (en) 2001-06-27
AU760435B2 (en) 2003-05-15
CZ2001879A3 (cs) 2001-08-15
US6852724B2 (en) 2005-02-08
AR022085A1 (es) 2002-09-04
DK1096937T3 (da) 2005-05-09
UA75027C2 (uk) 2006-03-15
US6369062B1 (en) 2002-04-09
IL141893A (en) 2008-08-07
KR20010089874A (ko) 2001-10-12
US6864258B2 (en) 2005-03-08
US6525057B2 (en) 2003-02-25
SI1109558T1 (en) 2002-10-31
ES2234302T3 (es) 2005-06-16
US20030099705A1 (en) 2003-05-29
LU91504I2 (fr) 2009-02-03
EP1096937A2 (en) 2001-05-09
RU2214233C2 (ru) 2003-10-20
DE69901570D1 (de) 2002-06-27
WO2000013687A3 (en) 2000-06-29
US20060147521A1 (en) 2006-07-06
NO2009005I1 (no) 2009-03-16
CA2343376A1 (en) 2000-03-16
WO2000013687A2 (en) 2000-03-16
AR052921A1 (es) 2007-04-11
HUP0104088A3 (en) 2002-12-28
PL196263B1 (pl) 2007-12-31
HU224215B1 (hu) 2005-06-28
NO20011191D0 (no) 2001-03-08
PL348249A1 (en) 2002-05-20
CN1211086C (zh) 2005-07-20
HK1044284B (zh) 2005-07-15
CY2008020I2 (el) 2010-07-28
IL141892A0 (en) 2002-03-10
NL300371I1 (nl) 2009-02-02
AR053440A2 (es) 2007-05-09
EP1527779A1 (en) 2005-05-04
PT1096937E (pt) 2005-04-29
GEP20053420B (en) 2005-01-25
DE69901570T2 (de) 2003-01-09
US20030166659A1 (en) 2003-09-04
NL300371I2 (nl) 2009-10-01
AU744071B2 (en) 2002-02-14
DE69922964D1 (de) 2005-02-03
US6562826B1 (en) 2003-05-13
TWI241911B (en) 2005-10-21
CY2008020I1 (el) 2010-07-28
HUP0103844A2 (hu) 2002-04-29
BR9913553A (pt) 2001-10-23
US20050059667A1 (en) 2005-03-17
US20020004506A1 (en) 2002-01-10
NO320986B1 (no) 2006-02-20
CN1193757C (zh) 2005-03-23
SI1096937T1 (en) 2005-04-30
JP3745621B2 (ja) 2006-02-15
UA67793C2 (uk) 2004-07-15
HK1040060A1 (en) 2002-05-24
US20020090396A1 (en) 2002-07-11
TR200101261T2 (tr) 2002-05-21
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
PT1109558E (pt) 2002-10-31
MXPA01002599A (es) 2005-02-17
IL141892A (en) 2006-08-20
NO20011192D0 (no) 2001-03-08
NO319434B1 (no) 2005-08-15
RU2207856C2 (ru) 2003-07-10
ATE285774T1 (de) 2005-01-15
AU2008207707A1 (en) 2008-09-25
FR09C0001I1 (es) 2009-02-27
FR09C0001I2 (es) 2009-12-18
MXPA01002598A (es) 2002-04-08
NO2009005I2 (es) 2010-06-28
CZ301375B6 (cs) 2010-02-03
DE69922964T2 (de) 2005-12-08
CN1321088A (zh) 2001-11-07
IL141893A0 (en) 2002-03-10
CA2342390C (en) 2006-08-29
JP2002524416A (ja) 2002-08-06
NZ510386A (en) 2003-08-29
CN1354665A (zh) 2002-06-19
AU2008207703A1 (en) 2008-09-25
HUP0104088A2 (hu) 2002-05-29
NO20011192L (no) 2001-04-30
US6303607B1 (en) 2001-10-16
US20060217397A1 (en) 2006-09-28
NZ510384A (en) 2002-10-25
PL196668B1 (pl) 2008-01-31
IL180864A0 (en) 2007-07-04
EP1109558B1 (en) 2002-05-22
IL175371A0 (en) 2006-09-05
CZ2001880A3 (cs) 2001-08-15
PL202207B1 (pl) 2009-06-30
CA2343376C (en) 2007-01-09
AU6142599A (en) 2000-03-27
US6503911B2 (en) 2003-01-07
US20050153982A1 (en) 2005-07-14
DK1109558T3 (da) 2002-08-26
JP2006096757A (ja) 2006-04-13
US20040097514A1 (en) 2004-05-20
EP1096937B1 (en) 2004-12-29
US20040029890A1 (en) 2004-02-12
LU91504I9 (es) 2019-01-02
AU6036499A (en) 2000-03-27
ATE217794T1 (de) 2002-06-15

Similar Documents

Publication Publication Date Title
ES2177346T3 (es) Formulaciones de ranolazina de liberacion lenta.
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
BR0015188A (pt) Composições farmacêuticas
BR0115382A (pt) Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
ATE380170T1 (de) Pharmazeutische verbindungen
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ATE340563T1 (de) DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ME00520B (me) Levodop/karbidop/entakapon farmaceutski preparat
CO5410187A1 (es) Formulacion oral de dosis unica de espinosad
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
BRPI0410116A (pt) tablete de cuidado oral
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
MY129310A (en) C-4 carbonate taxanes
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
AR029637A1 (es) Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
NZ523606A (en) Pharmaceutical compositions and methods for use